GlassScriptPhysician profile
Kristen Heard
NPI 1124468152
$3,567.65
in general payments reported to CMS, 2019-2025
27 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $280 · 2021: $530 · 2022: $957 · 2023: $794 · 2024: $485 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $890.03 | 2019-2025 | Grafix Pl, Stravix Pl, Stravix |
| Organogenesis INC. | $625.59 | 2020-2025 | Puraply, Novachor, Puraply Wound Matrix |
| Kerecis Limited | $327.01 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Novo Nordisk INC | $274.78 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $184.04 | 2019-2025 | Proclaim |
| Misonix INC | $124.99 | 2021 | |
| Lilly USA, LLC | $124.47 | 2022-2025 | Zepbound, Mounjaro, Emgality |
| Allergan, INC. | $112.51 | 2022 | |
| Polynovo North America LLC | $94.87 | 2022-2023 | |
| Averitas Pharma INC. | $91.87 | 2023-2024 | Qutenza |
| Abbvie INC. | $82.84 | 2021-2024 | |
| Amarin Pharma, INC. | $78.43 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $77.51 | 2019-2021 | |
| Mid-Atlantic Surgical Systems, LLC | $76.76 | 2019-2021 | |
| Amgen INC. | $70.59 | 2022-2023 | Otezla, Repatha |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $49.12 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Bioventus LLC | $48.28 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Kci USA, INC. | $35.95 | 2023 | Activ.A.C. |
| Paratek Pharmaceuticals, INC. | $35.12 | 2023-2024 | Nuzyra |
| Zimmer Biomet Holdings, INC. | $30.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.66 | 2022-2024 | Synjardy, Jardiance |
| Glaxosmithkline, LLC. | $23.40 | 2024 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $17.26 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.07 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.64 | 2021 | |
| Ebi, LLC | $14.57 | 2025 | Biomet Ebi Bone Healing System |
| Stryker Corporation | $14.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Heard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.